<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 8)*
CECO Environmental Corp.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
001-858-109
----------------------------------------
(CUSIP Number)
Phillip DeZwirek
505 University Avenue, Suite 1400
Toronto, Ontario CANADA M5G 1X3
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to Receive Notices
and Communications)
April 7, 2000
------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisitions which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The Remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the act (however, see the
Notes).
<PAGE>
_______________________________________________________________________________
CUSIP No. 001-858-109 SCHEDULE 13D Page 2 of 12 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Icarus Investment Corp.
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
00 (no change of ownership is reported)
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(E) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 1,334,360
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | 1,800,000
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 1,334,360
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| | 1,800,000
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,134,360
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
30.76%
______________________________________________________________________________
14 TYPE OF REPORTING PERSON
CO
______________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
_______________________________________________________________________________
CUSIP No. 001-858-109 SCHEDULE 13D Page 3 of 12 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Phillip DeZwirek
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
00 (no change of ownership is reported)
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(E) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Candian citizen
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 1,755,497
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | 3,134,360
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 1,755,497
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| | 3,134,360
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,889,857
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
40.96%
______________________________________________________________________________
14 TYPE OF REPORTING PERSON*
IN
______________________________________________________________________________
<PAGE>
_______________________________________________________________________________
CUSIP No. 001-858-109 SCHEDULE 13D Page 4 of 12 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Jason Louis DeZwirek
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
00 (no change of ownership is reported)
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(E) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Canadian citizen
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 1,598,666
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | | 3,134,360
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 1,598,666
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| | 3,134,360
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,733,026
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
46.45%
______________________________________________________________________________
14 TYPE OF REPORTING PERSON
IN
______________________________________________________________________________
<PAGE>
_______________________________________________________________________________
CUSIP No. 001-858-109 SCHEDULE 13D Page 5 of 12 Pages
_______________________________________________________________________________
1 NAME OF REPORTING PERSON
S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Can-Med Technology, Inc. d/b/a Green Diamond Corp.
______________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
______________________________________________________________________________
3 SEC USE ONLY
______________________________________________________________________________
4 SOURCE OF FUNDS*
WC
______________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) OR 2(E) [ ]
______________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Ontario
_______________________________________________________________________________
| |
NUMBER OF | 7 | SOLE VOTING POWER
SHARES | | 1,800,000
BENEFICIALLY |_____|________________________________________________________
OWNED BY | |
EACH | 8 | SHARED VOTING POWER
REPORTING | |
PERSON WITH |_____|________________________________________________________
| |
| 9 | SOLE DISPOSITIVE POWER
| | 1,800,000
|_____|________________________________________________________
| |
| 10 | SHARED DISPOSITIVE POWER
| |
_______________|_____|_________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,800,000
______________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES [ ]
______________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
17.67%
______________________________________________________________________________
14 TYPE OF REPORTING PERSON
CO
______________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT
<PAGE>
SCHEDULE 13D
CUSIP NO. 001-858-109 PAGE 6 OF 12 PAGES
Amendment No. 8 to Schedule 13D filed by Icarus Investment Corp.
("Icarus"), Phillip DeZwirek, Jason Louis DeZwirek and Can-Med Technology, Inc.
("Can-Med") relating to the issuance of warrants to purchase 800,000 shares of
common stock of CECO Environmental Corp. ("CECO") to Can-Med. Can-Med also
operates under the name Green Diamond Corp.
Items 3-7 inclusive for Icarus Investment Corp. ("Icarus")
Item 3. Sources and Amount of Funds or Other Consideration.
See response to item 3 for Can-Med. Icarus owns 50.1% of the
outstanding stock of Can-Med. Mr. Phillip DeZwirek and Mr. Jason DeZwirek each
own 50% of the outstanding stock of Icarus.
Item 4. Purpose of the Transaction.
See response to item 4 for Can-Med.
Item 5. Interest in the Securities of the Issuer.
(a) Icarus beneficially owns 3,134,360 shares of common stock of CECO
or 30.76% of the outstanding common stock of CECO. Icarus owns 13.10% of such
shares directly and 17.66% of such shares indirectly through its 51% ownership
of Can-Med.
(b) Icarus has sole voting power and sole dispositive power with
respect to the 1,334,360 shares of common stock of CECO that it owns directly
and shared voting power and shared dispositive power with respect to the
securities underlying the warrants to purchase 1,800,000 shares of common stock
of CECO it owns indirectly. Such power is shared with Mr. Phillip DeZwirek and
Mr. Jason DeZwirek, who each own 50% of Icarus, and Can-Med, which owns such
securities directly.
(c) Icarus has not engaged in any transaction in the common stock of
CECO in the past 60 days.
(d) No other person (other than the principals of Icarus identified
above) is known to have the right to receive or the power to direct the receipt
of dividends from or the proceeds from the sale of, the common stock of CECO
owned directly by Icarus and no person other than Mr. Phillip DeZwirek, Mr.
Jason DeZwirek and Can-Med are known to have the right to receive or the power
to direct the receipt of dividends from or the proceeds from the sale of, the
securities underlying the warrants to purchase 1,800,000 shares of common stock
of CECO that Can-Med owns indirectly. The interests of Can-Med, Icarus, Phillip
DeZwirek and Jason DeZwirek in the common stock of CECO relate to more than 5%
interest in the common stock of CECO.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
None.
Item 7. Material to be Filed as Exhibits.
A joint filing statement is filed as an exhibit to this Amendment No. 8
to Schedule 13D.
<PAGE>
SCHEDULE 13D
CUSIP NO. 001-858-109 PAGE 7 OF 12 PAGES
Items 3-7 inclusive for Phillip DeZwirek.
Item 3. Source and Amount of Funds or Other Considerations.
See response to Item 3 for Can-Med and Icarus. Mr. Phillip DeZwirek and
Mr. Jason DeZwirek each own 50% of the outstanding stock of Icarus
Item 4. Purpose of Transaction.
See response to Item 4 for Can-Med.
Item 5. Interest in Securities of the Issuer.
(a) Phillip DeZwirek is deemed to beneficially own all securities
underlying the 1,800,000 warrants to purchase shares of common stock of CECO
held by Can-Med, all 1,334,360 shares of common stock of CECO owned directly by
Icarus and the 5,497 shares of CECO that he owns directly and the securities
underlying the warrants he owns directly to purchase 1,750,000 shares of common
stock of CECO, which represents 40.96% of the outstanding common stock of CECO
(including as outstanding the securities underlying the warrants to purchase
1,750,000 shares of common stock of CECO held by Mr. DeZwirek and the securities
underlying the warrants to purchase 1,800,000 shares of common stock of CECO
held by Can-Med). Of such amount 15.08% is attributable to Mr. DeZwirek's
ownership of shares of common stock of CECO indirectly through Can-Med, 11.18%
is attributable to Mr. DeZwirek's ownership of shares of common stock of CECO
indirectly through Icarus and 14.70% is attributable to Mr. DeZwirek's direct
ownership of shares of and warrants for common stock of CECO.
(b) As a result of Phillip DeZwirek being the Chief Executive Officer
and a 50% shareholder of Icarus, and Icarus' 50.1% ownership of Can-Med, Mr.
DeZwirek controls Icarus and Can-Med. Phillip DeZwirek has shared voting power
and shared dispositive power with respect to the 1,334,360 shares of common
stock of CECO owned by Icarus and the securities underlying the warrants to
purchase 1,800,000 shares of common stock of CECO owned by Can-Med. Such power
is shared with Jason DeZwirek, Icarus and Can-Med. Phillip DeZwirek has sole
voting and sole dispositive power with respect to the 5,497 shares of common
stock of CECO and the warrants to purchase 1,750,000 shares of common stock of
CECO that he owns directly.
(c) Phillip DeZwirek has not engaged in any transaction in common stock
of CECO during the past 60 days.
(d) Phillip DeZwirek controls Icarus. Icarus controls Can-Med. Icarus
owns 50.1% of the outstanding stock of Can-Med. Phillip DeZwirek owns 50% of the
outstanding stock of Icarus. Mr. Jason Louis DeZwirek is the only person other
than Phillip DeZwirek and Icarus who is known to have the right to receive or
the power to direct the receipt of dividends from, or the proceeds of the sale
of, the shares of common stock of CECO owned by Icarus and the only person other
than Phillip DeZwirek, Icarus and Can-Med who is known to have the right to
receive or the power to direct the receipt of dividends from, or the proceeds
from the sale of the warrants to purchase 1,800,000 shares of common stock of
CECO owned by Can-Med. Phillip DeZwirek is the only person known to have the
right to receive or the power to direct the receipt of dividends from, or the
proceeds of the 1,755,497 shares of the common stock of CECO, including the
common stock underlying the 1,750,000 warrants to purchase common stock of CECO,
owned directly by him. The interests of Can-Med, Icarus, Phillip DeZwirek and
Jason DeZwirek in the common stock of CECO relate to more than 5% interests in
the common stock of CECO.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
None
Item 7. Material to be Filed as Exhibits.
A joint filing statement is filed as an exhibit to this Amendment No. 8
to Schedule 13D.
<PAGE>
SCHEDULE 13D
CUSIP NO. 001-858-109 PAGE 8 OF 12 PAGES
Item 3-7 inclusive for Jason Louis DeZwirek.
Item 3. Sources and Amount of Funds or Other Consideration.
See response to Item 3 for Can-Med and Icarus. Mr. Jason DeZwirek and
Mr. Phillip DeZwirek each own 50% of the outstanding stock of Icarus.
Item 4. Purpose of Transaction.
See response to Item 4 for Can-Med.
Item 5. Interest in Securities of Issuer.
(a) Jason Louis DeZwirek beneficially owns 4,733,026 shares or 46.45% of the
outstanding common stock of CECO, including as outstanding the securities
underlying the warrants to purchase 1,800,000 shares of common stock of CECO
owned by Can-Med.
(b) Jason Louis DeZwirek owns 1,598,666 shares of CECO common stock
through IntroTech, representing 15.69% of the outstanding common stock of CECO.
Mr. DeZwirek has sole voting and sole dispositive power with respect to such
shares. Mr. DeZwirek has shared voting and shared dispositive power with respect
to the 1,334,360 shares of CECO owned by Icarus, which represent 13.10% of
CECO's outstanding common stock. Mr. DeZwirek has shared voting and shared
dispositive power with respect to the securities underlying the warrants to
purchase 1,800,000 shares of common stock of CECO owned by Can-Med, which
represent 17.67% of CECO's outstanding common stock. Jason Louis DeZwirek shares
voting and dispositive power with respect to the 1,334,360 shares of CECO common
stock owned by Icarus and the securities underlying the warrants to purchase
1,800,000 shares of common stock of CECO owned by Can-Med with Phillip DeZwirek
and Icarus. Icarus owns 50.1% of the outstanding stock of Can-Med. Phillip
DeZwirek and Jason Louis DeZwirek each own 50% of the stock of Icarus. Jason
Louis DeZwirek is the adult son of Phillip DeZwirek. For all calculations for
this Item 5(b) the outstanding stock of CECO includes as outstanding the
securities underlying the warrants to purchase 1,800,000 shares of common stock
of CECO owned by Can-Med.
(c) Jason Louis DeZwirek has not engaged in any transaction in common
stock of CECO in the past 60 days.
(d) Jason Louis DeZwirek controls Icarus. Icarus owns 50.1% of the
outstanding stock of Can-Med. Jason Louis DeZwirek owns 50% of the outstanding
stock of Icarus. Icarus and Phillip DeZwirek are the only persons, other than
Jason Louis DeZwirek, who are known to have the right to receive or the power to
direct the receipt of dividends from, or the proceeds of the sale of, the shares
of CECO owned by Icarus. No persons other than Jason Louis DeZwirek, Mr. Phillip
DeZwirek, Icarus and Can-Med are known to have the right to receive or the power
to direct the receipt of dividends from or the proceeds from the sale of the
securities underlying the warrants to purchase 1,800,000 shares of common stock
of CECO owned by Can-Med directly. The interests of Can-Med, Icarus, Jason Louis
DeZwirek and Phillip DeZwirek in the common stock of CECO relate to more than 5%
interests in the common stock of CECO.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
Securities of the Issuer.
None.
Item 7. Material to be Filed as Exhibits.
A joint filing statement is filed as an exhibit to this Amendment No. 8
to Schedule 13D.
<PAGE>
SCHEDULE 13D
CUSIP NO. 001-858-109 PAGE 9 OF 12 PAGES
Items 1-7 inclusive for Can-Med Technology, Inc.
Item 1. Security and Issuer.
CECO Environmental Corp.
505 University Avenue
Suite 1400
Toronto, Ontario
Canada M5G 1X3
Item 2. Identity and Background:
(a) Can-Med Technology, Inc., an Ontario corporation
(b) Address of Principal Business:
505 University Avenue, Suite 1400
Toronto, Ontario Canada M5G 1X3
(c) Principal Business: Can-Med is an Ontario public company whose
principal business is managing its own investments.
(d) Can-Med has not been involved in any criminal proceedings.
(e) Can-Med has never been a party to any civil judicial or
administrative proceeding in which there has been any finding of any violation
of any federal or state securities laws.
Item 3. Source and Amount of Funds or Other Considerations.
Can-Med purchased the warrants to purchase 800,000 shares of common
stock of CECO with its own capital.
Item 4. Purpose of Transaction.
On December 7, 1999,Can-Med received warrants to purchase 800,000
shares of common stock of CECO exercisable on or after June 7, 2000 in partial
consideration for making a $4,000,000 subordinated loan to CECO. The loan was
made in connection with CECO's acquisition of The Kirk & Blum Manufacturing
Company and kbd/Technics Inc. Can-Med purchased the warrants to purchase 800,000
shares of common stock of CECO for investment and, with respect to itself, its
direct owner, Icarus Investment Corp. and indirect ultimate owners, Phillip
DeZwirek and Jason DeZwirek, for purposes of control of CECO.
Item 5. Interest in Securities of the Issuer.
(a) Can-Med is deemed to beneficially own all of the securities
underlying the warrants to purchase 1,800,000 shares of common stock of CECO,
which represents 17.67% of the outstanding common stock of CECO (including as
outstanding the securities underlying the warrants to purchase 1,800,000 shares
of common stock of CECO). Of such amount, the entire 17.67% is attributable to
Can-Med's direct ownership of shares of common stock of CECO.
(b) Can-Med has sole voting and sole dispositive power with respect to
the warrants to purchase 1,800,000 shares of common stock of CECO that it is
deemed to own directly.
(c) Can-Med has not engaged in any transactions in common stock of CECO
in the past 60 days.
<PAGE>
SCHEDULE 13D
CUSIP NO. 001-858-109 PAGE 10 OF 12 PAGES
(d) Icarus owns 50.1% of the outstanding stock of Can-Med. Phillip
DeZwirek and Jason DeZwirek control Icarus, each owning 50% of the outstanding
stock of Icarus. Can-Med, Icarus, Phillip DeZwirek and Jason DeZwirek are the
only persons who are known to have the right to receive or the power to direct
the receipt of dividends from, or the proceeds of the sale of, the shares of
common stock of CECO underlying the warrants to purchase 1,800,000 shares of
CECO owned by Can-Med. The interests of Can-Med, Icarus, Phillip DeZwirek and
Jason DeZwirek in the common stock of CECO relate to more than 5% interests in
the common stock of CECO.
(e) Not applicable.
Item 6. Contracts, Arrangements, Understanding or Relationships with Respect to
Securities of the Issuer.
None.
Item 7. Material to be Filed as Exhibits.
A joint filing statement is files as an exhibit to this Amendment No. 8
to Schedule 13D.
<PAGE>
Signatures
After reasonable inquiry and to the best of our knowledge and belief,
the undersigned certify that the information set forth in this statement is
true, complete and correct.
Dated: May 16, 2000 ICARUS INVESTMENT CORP.
By: /s/ Phillip DeZwirek
-------------------------
Phillip DeZwirek
Chief Executive Officer
/s/ Phillip DeZwirek
-------------------------
Phillip DeZwirek
/s/ Jason Louis DeZwirek
-------------------------
Jason Louis DeZwirek
CAN-MED TECHNOLOGY, INC.
By: /s/ Phillip DeZwirek
-------------------------
Phillip DeZwirek
President
<PAGE>
EXHIBIT TO AMENDMENT NO. 8 TO SCHEDULE 13D
DATED May 16, 2000
OF
ICARUS INVESTMENT CORP.
PHILLIP DEZWIREK
JASON LOUIS DEZWIREK
AND CAN-MED TECHNOLOGY, INC.
JOINT FILING AGREEMENT
Icarus Investment Corp. ("Icarus"), Phillip DeZwirek ("DeZwirek"),
Jason Louis DeZwirek ("JLD") and Can-Med Technology, Inc. ("Can-Med") hereby
agree that the Amendment No. 8 to Schedule 13D to which this statement is
attached is filed on behalf of Icarus, DeZwirek, JLD and Can-Med and that any
amendments to this Schedule 13D may be filed on behalf of Icarus, DeZwirek, JLD
and Can-Med.
ICARUS INVESTMENT CORP.
By: /s/ Phillip DeZwirek
------------------------
Phillip DeZwirek
Chief Executive Officer
/s/ Phillip DeZwirek
------------------------
Phillip DeZwirek
/s/ Jason Louis DeZwirek
------------------------
Jason Louis DeZwirek
CAN-MED TECHNOLOGY, INC.
By: /s/ Phillip DeZwirek
------------------------
Phillip DeZwirek
President
